Abstract:Background: Bladder cancer has become the tenth most diagnosed cancer worldwide. The prognosis has been shown to differ between non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). We aimed to identify signature genes that are associated with the invasiveness and survival of bladder cancer and to identify potential treatments. Methods: We downloaded gene expression profiles of bladder cancer from the Gene Expression Omnibus database to identify differentially expressed genes and perform weighted gene co-expression network analysis. Functional enrichment was analyzed by GO and KEGG analyses. Hub genes were identified from the significant module. Another dataset was also acquired to verify the expression of hub genes. Univariate and multivariate Cox regression analyses were applied to the dataset downloaded from The Cancer Genome Atlas database. Risk scores were calculated and the effect was evaluated by Kaplan-Meier survival analysis. A nomogram was constructed and validated using training and testing samples, respectively. Analysis of the tumor immune microenvironment was conducted with the CIBERSORT algorithm. Results: In total, 1,245 differentially expressed genes (DEGs) were identified. A distinct module was identified that was significantly correlated to invasiveness. The genes within this module were found to be significantly associated with extracellular exosomes, GTPase activity, metabolic pathways, etc. Three hub genes (VSIG2, PPFIBP2, and DENND2D) were identified as biomarkers of invasiveness; two of these (PPFIBP2 and DENND2D) were closely associated with prognosis. The risk score was regarded as an independent prognostic factor. The nomogram was associated with acceptable accuracy for predicting 1- and 5-year overall survival. The infiltrating levels of resting NK cells, activated natural killer (NK) cells, CD8 + T cells, activated memory CD4 + T cells, and T follicular helper cells, were significantly higher in the group with lower risk scores. The group with higher risk scores showed predominant infiltration by regulatory T cells (Tregs). Conclusion: We successfully identified three signature genes related to invasiveness and constructed a nomogram of bladder cancer with acceptable performance. Differences suggested by risk scores between groups of patients showing diverse patterns of immune cell infiltration may be beneficial for selecting therapeutic approaches and predicting prognosis.

Identification of an immune gene-associated prognostic signature in patients with bladder cancer

Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer

Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma

Identification of an Immune-Related Long Non-Coding RNA Signature and Nomogram As Prognostic Target for Muscle-Invasive Bladder Cancer

Bioinformatics Analysis Finds Immune Gene Markers Related to the Prognosis of Bladder Cancer.

An Individualized Prognostic Signature for Clinically Predicting the Survival of Patients With Bladder Cancer

Identification of immune-related genes that predict prognosis and risk of bladder cancer: bioinformatics analysis of TCGA database

Identification and Validation of A Hypoxia-Related Prognostic and Immune Microenvironment Signature in Bladder Cancer

Integrated Analysis Identifies and Validates a Novel Signature Based on Immune Related Gene Predicting Survival in Bladder Urothelial Carcinoma

Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer

Development and verification of immune-related long non-coding RNA prognostic signature in bladder cancer

Identification of a Novel Immune Microenvironment Signature Predicting Survival and Therapeutic Options for Bladder Cancer.

Identification of tumor-specific T cell signature predicting cancer immunotherapy response in bladder cancer by multi-omics analysis and experimental verification

Identification and Verification of an Immune-Related Lncrna Signature for Predicting the Prognosis of Patients with Bladder Cancer.

Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer

Development of a prognostic signature for bladder cancer based on immune-related genes

Clinical Significance and Tumor Microenvironment Characterization of a Novel Immune-Related Gene Signature in Bladder Cancer

Identification of bladder cancer subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes

A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer

Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer

Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer